Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell
therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell …

The immune system evolved to distinguish non-self from self to protect the organism. As
cancer is derived from our own cells, immune responses to dysregulated cell growth present …

Chimeric antigen receptor (CAR) T-cell therapy is highly effective in the treatment of B-cell
acute lymphoblastic leukemia (ALL) or B-cell lymphoma, providing alternative therapeutic …

BACKGROUND. T cells expressing antigen-specific chimeric antigen receptors (CARs)
improve outcomes for CD19-expressing B cell malignancies. We evaluated a human …

Adoptive transfer of T cells genetically modified to express chimeric antigen receptors
(CARs) targeting CD19 has produced impressive results in treating patients with B-cell …

Most B-cell malignancies express CD19, and a majority of patients with B-cell malignancies
are not cured by current standard therapies. Chimeric antigen receptors (CARs) are fusion …

Summary On July 1, 2014, the United States Food and Drug Administration granted
'breakthrough therapy'designation to CTL 019, the anti‐CD 19 chimeric antigen receptor T …

Improved outcomes for patients with cancer hinge on the development of new targeted
therapies with acceptable short-term and long-term toxicity. Progress in basic, preclinical …

Long-term engraftment of allogeneic cells necessitates eluding immune-mediated rejection,
which is currently achieved by matching for human leukocyte antigen (HLA) expression …

Many B‐cell acute and chronic leukaemias tend to be resistant to killing by natural killer (NK)
cells. The introduction of chimeric antigen receptors (CAR) into T cells or NK cells could …